{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:58:51Z","timestamp":1761843531952},"reference-count":45,"publisher":"American Association for Cancer Research (AACR)","issue":"13","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Purpose: The main procedure to confirm a suspected diagnosis of prostate cancer is histologic analysis of ultrasound-guided sextant prostate biopsies. As it is difficult to reliably assess tumor stage and grade in such minute samples, the clinical significance of some tumor foci remains unclear. Genetic markers that could augment pretreatment prognostic information would improve the clinical management of the disease.<\/jats:p>\n               <jats:p>Experimental Design: We have analyzed by comparative genomic hybridization a consecutive series of prostate needle biopsies obtained prospectively from 100 prostate cancer suspects. For 25 of these patients, a second independent biopsy core was analyzed to assess possible tumor heterogeneity. Additionally, a three-color fluorescent in situ hybridization assay was done in paraffin-embedded biopsy cores to validate the comparative genomic hybridization findings and to confirm their prognostic value.<\/jats:p>\n               <jats:p>Results: Sixty-one of 100 biopsy samples had morphologic evidence of prostate cancer and 41 (67%) of these displayed genomic copy number changes as opposed to none of the morphologically normal biopsies. The presence of losses, amplifications, and the total number of genomic imbalances were significantly associated with poorly differentiated tumors. Kaplan-Meier curves with log-rank test showed that patients whose tumors displayed 8q gains had a significantly worse survival even when tumor grade was taken into account (P = 0.008). Restricting the analysis to cases with Gleason score 7, the most troublesome category in terms of prognostic information, gains at 8q were still significantly associated with poor survival (P = 0.011), something that was confirmed by fluorescent in situ hybridization in an independent series of biopsies with much longer follow-up time (P = 0.023).<\/jats:p>\n               <jats:p>Conclusions: We show that whole genomic information can be obtained from minute needle biopsies of prostate cancer suspects and that genetic data can provide additional prognostic information before a therapeutic decision is taken.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-05-1977","type":"journal-article","created":{"date-parts":[[2006,7,5]],"date-time":"2006-07-05T20:54:13Z","timestamp":1152132853000},"page":"3961-3970","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["8q Gain Is an Independent Predictor of Poor Survival in Diagnostic Needle Biopsies from Prostate Cancer Suspects"],"prefix":"10.1158","volume":"12","author":[{"given":"Franclim R.","family":"Ribeiro","sequence":"first","affiliation":[{"name":"1Genetics, Departments of"},{"name":"7Department of Genetics, Institute for Cancer Research, Norwegian Radium Hospital; and"}]},{"given":"Carmen","family":"Jero\u0301nimo","sequence":"additional","affiliation":[{"name":"1Genetics, Departments of"},{"name":"5Fernando Pessoa University;"}]},{"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[{"name":"2Pathology,"},{"name":"6Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences, University of Porto, Porto, Portugal;"}]},{"given":"Daniel","family":"Fonseca","sequence":"additional","affiliation":[{"name":"3Radiology, and"}]},{"given":"Jorge","family":"Oliveira","sequence":"additional","affiliation":[{"name":"4Urology, Portuguese Oncology Institute-Porto;"}]},{"given":"Ragnhild A.","family":"Lothe","sequence":"additional","affiliation":[{"name":"7Department of Genetics, Institute for Cancer Research, Norwegian Radium Hospital; and"},{"name":"8Department of Molecular Biosciences, University of Oslo, Oslo, Norway"}]},{"given":"Manuel R.","family":"Teixeira","sequence":"additional","affiliation":[{"name":"1Genetics, Departments of"},{"name":"6Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences, University of Porto, Porto, Portugal;"}]}],"member":"1086","published-online":{"date-parts":[[2006,7,3]]},"reference":[{"key":"2022061114022633400_B1","doi-asserted-by":"crossref","unstructured":"Terris MK, McNeal JE, Stamey TA. Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J Urol\u20081992;148:829\u201332.","DOI":"10.1016\/S0022-5347(17)36735-6"},{"key":"2022061114022633400_B2","doi-asserted-by":"crossref","unstructured":"Stamey TA. Making the most out of six systematic sextant biopsies. Urology\u20081995;45:2\u201312.","DOI":"10.1016\/S0090-4295(95)96168-2"},{"key":"2022061114022633400_B3","doi-asserted-by":"crossref","unstructured":"King CR, Long JP. Prostate biopsy grading errors: a sampling problem? Int J Cancer\u20082000;90:326\u201330.","DOI":"10.1002\/1097-0215(20001220)90:6<326::AID-IJC3>3.0.CO;2-J"},{"key":"2022061114022633400_B4","doi-asserted-by":"crossref","unstructured":"Mills SE, Fowler JE, Jr. Gleason histologic grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens. Cancer\u20081986;57:346\u20139.","DOI":"10.1002\/1097-0142(19860115)57:2<346::AID-CNCR2820570226>3.0.CO;2-E"},{"key":"2022061114022633400_B5","doi-asserted-by":"crossref","unstructured":"Bostwick DG. Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol\u20081994;18:796\u2013803.","DOI":"10.1097\/00000478-199408000-00006"},{"key":"2022061114022633400_B6","doi-asserted-by":"crossref","unstructured":"Peller PA, Young DC, Marmaduke DP, Marsh WL, Badalament RA. Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens. Cancer\u20081995;75:530\u20138.","DOI":"10.1002\/1097-0142(19950115)75:2<530::AID-CNCR2820750216>3.0.CO;2-Y"},{"key":"2022061114022633400_B7","doi-asserted-by":"crossref","unstructured":"Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol\u20081997;21:566\u201376.","DOI":"10.1097\/00000478-199705000-00010"},{"key":"2022061114022633400_B8","doi-asserted-by":"crossref","unstructured":"King CR. Patterns of prostate cancer biopsy grading: trends and clinical implications. Int J Cancer\u20082000;90:305\u201311.","DOI":"10.1002\/1097-0215(20001220)90:6<305::AID-IJC1>3.0.CO;2-U"},{"key":"2022061114022633400_B9","doi-asserted-by":"crossref","unstructured":"Koksal IT, Ozcan F, Kadioglu TC, Esen T, Kilicaslan I, Tunc M. Discrepancy between Gleason scores of biopsy and radical prostatectomy specimens. Eur Urol\u20082000;37:670\u20134.","DOI":"10.1159\/000020216"},{"key":"2022061114022633400_B10","doi-asserted-by":"crossref","unstructured":"Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol\u20082001;166:104\u20139.","DOI":"10.1016\/S0022-5347(05)66086-7"},{"key":"2022061114022633400_B11","doi-asserted-by":"crossref","unstructured":"Smith EB, Frierson HF, Jr., Mills SE, Boyd JC, Theodorescu D. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading? Cancer\u20082002;94:2282\u20137.","DOI":"10.1002\/cncr.10457"},{"key":"2022061114022633400_B12","doi-asserted-by":"crossref","unstructured":"Sved PD, Gomez P, Manoharan M, Kim SS, Soloway MS. Limitations of biopsy Gleason grade: implications for counseling patients with biopsy Gleason score 6 prostate cancer. J Urol\u20082004;172:98\u2013102.","DOI":"10.1097\/01.ju.0000132135.18093.d6"},{"key":"2022061114022633400_B13","doi-asserted-by":"crossref","unstructured":"Fu W, Bubendorf L, Willi N, et al. Genetic changes in clinically organ-confined prostate cancer by comparative genomic hybridization. Urology\u20082000;56:880\u20135.","DOI":"10.1016\/S0090-4295(00)00722-6"},{"key":"2022061114022633400_B14","doi-asserted-by":"crossref","unstructured":"Alers JC, Krijtenburg PJ, Vis AN, et al. Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies: early cancers may contain aggressive genetic features. Am J Pathol\u20082001;158:399\u2013406.","DOI":"10.1016\/S0002-9440(10)63983-1"},{"key":"2022061114022633400_B15","doi-asserted-by":"crossref","unstructured":"Wolter H, Gottfried HW, Mattfeldt T. Genetic changes in stage pT2N0 prostate cancer studied by comparative genomic hybridization. BJU Int\u20082002;89:310\u20136.","DOI":"10.1046\/j.1464-4096.2001.01722.x"},{"key":"2022061114022633400_B16","doi-asserted-by":"crossref","unstructured":"Chu LW, Troncoso P, Johnston DA, Liang JC. Genetic markers useful for distinguishing between organ-confined and locally advanced prostate cancer. Genes Chromosomes Cancer\u20082003;36:303\u201312.","DOI":"10.1002\/gcc.10171"},{"key":"2022061114022633400_B17","unstructured":"Visakorpi T, Kallioniemi AH, Syva\u0308nen AC, et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res\u20081995;55:342\u20137."},{"key":"2022061114022633400_B18","unstructured":"Cher ML, Bova GS, Moore DH, et al. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res\u20081996;56:3091\u2013102."},{"key":"2022061114022633400_B19","doi-asserted-by":"crossref","unstructured":"Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol\u20081998;153:141\u20138.","DOI":"10.1016\/S0002-9440(10)65554-X"},{"key":"2022061114022633400_B20","doi-asserted-by":"crossref","unstructured":"Alers JC, Rochat J, Krijtenburg PJ, et al. Identification of genetic markers for prostatic cancer progression. Lab Invest\u20082000;80:931\u201342.","DOI":"10.1038\/labinvest.3780096"},{"key":"2022061114022633400_B21","doi-asserted-by":"crossref","unstructured":"Ross JS, Sheehan CE, Ambros RA, et al. Needle biopsy DNA ploidy status predicts grade shifting in prostate cancer. Am J Surg Pathol\u20081999;23:296\u2013301.","DOI":"10.1097\/00000478-199903000-00008"},{"key":"2022061114022633400_B22","doi-asserted-by":"crossref","unstructured":"Sebo TJ, Cheville JC, Riehle DL, et al. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Cancer\u20082001;91:2196\u2013204.","DOI":"10.1002\/1097-0142(20010601)91:11<2196::AID-CNCR1249>3.0.CO;2-#"},{"key":"2022061114022633400_B23","unstructured":"Takahashi S, Qian J, Brown JA, et al. Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res\u20081994;54:3574\u20139."},{"key":"2022061114022633400_B24","doi-asserted-by":"crossref","unstructured":"Henke RP, Kru\u0308ger E, Ayhan N, Hu\u0308bner D, Hammerer P. Frequency and distribution of numerical chromosomal aberrations in prostatic cancer. Hum Pathol\u20081994;25:476\u201384.","DOI":"10.1016\/0046-8177(94)90119-8"},{"key":"2022061114022633400_B25","doi-asserted-by":"crossref","unstructured":"Henke RP, Hammerer P, Graefen M, et al. Interphase cytogenetic study of preoperative core biopsies for the prediction of early serum prostate specific antigen recurrence after radical prostatectomy of clinically localized prostate carcinoma. Cancer\u20081998;83:977\u201388.","DOI":"10.1002\/(SICI)1097-0142(19980901)83:5<977::AID-CNCR25>3.0.CO;2-R"},{"key":"2022061114022633400_B26","doi-asserted-by":"crossref","unstructured":"Al Maghrabi J, Vorobyova L, Toi A, Chapman W, Zielenska M, Squire JA. Identification of numerical chromosomal changes detected by interphase fluorescence in situ hybridization in high-grade prostate intraepithelial neoplasia as a predictor of carcinoma. Arch Pathol Lab Med\u20082002;126:165\u20139.","DOI":"10.5858\/2002-126-0165-IONCCD"},{"key":"2022061114022633400_B27","unstructured":"Matsuyama H, Pan Y, Skoog L, et al. Deletion mapping of chromosome 8p in prostate cancer by fluorescence in situ hybridization. Oncogene\u20081994;9:3071\u20136."},{"key":"2022061114022633400_B28","doi-asserted-by":"crossref","unstructured":"Bastacky S, Cieply K, Sherer C, Dhir R, Epstein JI. Use of interphase fluorescence in situ hybridization in prostate needle biopsy specimens with isolated high-grade prostatic intraepithelial neoplasia as a predictor of prostate adenocarcinoma on follow-up biopsy. Hum Pathol\u20082004;35:281\u20139.","DOI":"10.1016\/j.humpath.2003.10.019"},{"key":"2022061114022633400_B29","doi-asserted-by":"crossref","unstructured":"Jeronimo C, Usadel H, Henrique R, et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst\u20082001;93:1747\u201352.","DOI":"10.1093\/jnci\/93.22.1747"},{"key":"2022061114022633400_B30","doi-asserted-by":"crossref","unstructured":"Harden SV, Sanderson H, Goodman SN, et al. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J Natl Cancer Inst\u20082003;95:1634\u20137.","DOI":"10.1093\/jnci\/djg082"},{"key":"2022061114022633400_B31","doi-asserted-by":"crossref","unstructured":"Dreher T, Zentgraf H, Abel U, et al. Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Arch\u20082004;444:509\u201317.","DOI":"10.1007\/s00428-004-1004-6"},{"key":"2022061114022633400_B32","doi-asserted-by":"crossref","unstructured":"Zhou M, Tokumaru Y, Sidransky D, Epstein JI. Quantitative GSTP1 methylation levels correlate with Gleason grade and tumor volume in prostate needle biopsies. J Urol\u20082004;171:2195\u20138.","DOI":"10.1097\/01.ju.0000127728.71350.36"},{"key":"2022061114022633400_B33","doi-asserted-by":"crossref","unstructured":"Teixeira MR, Ribeiro FR, Eknaes M, et al. Genomic analysis of prostate carcinoma specimens obtained via ultrasound-guided needle biopsy may be of use in preoperative decision-making. Cancer\u20082004;101:1786\u201393.","DOI":"10.1002\/cncr.20527"},{"key":"2022061114022633400_B34","doi-asserted-by":"crossref","unstructured":"Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol\u20081974;111:58\u201364.","DOI":"10.1016\/S0022-5347(17)59889-4"},{"key":"2022061114022633400_B35","doi-asserted-by":"crossref","unstructured":"Kallioniemi OP, Kallioniemi A, Piper J, et al. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer\u20081994;10:231\u201343.","DOI":"10.1002\/gcc.2870100403"},{"key":"2022061114022633400_B36","doi-asserted-by":"crossref","unstructured":"Ribeiro FR, Diep CB, Jeronimo C, et al. Statistical dissection of genetic pathways involved in prostate carcinogenesis. Genes Chromosomes Cancer\u20082006;45:154\u201363.","DOI":"10.1002\/gcc.20279"},{"key":"2022061114022633400_B37","doi-asserted-by":"crossref","unstructured":"Kirchhoff M, Gerdes T, Rose H, Maahr J, Ottesen AM, Lundsteen C. Detection of chromosomal gains and losses in comparative genomic hybridization analysis based on standard reference intervals. Cytometry\u20081998;31:163\u201373.","DOI":"10.1002\/(SICI)1097-0320(19980301)31:3<163::AID-CYTO3>3.0.CO;2-M"},{"key":"2022061114022633400_B38","unstructured":"ISCN 1995. An international system for human cytogenetic nomenclature. Basel: S. Karger; 1995."},{"key":"2022061114022633400_B39","doi-asserted-by":"crossref","unstructured":"Dysvik B, Jonassen I. J-Express: exploring gene expression data using Java. Bioinformatics\u20082001;17:369\u201370.","DOI":"10.1093\/bioinformatics\/17.4.369"},{"key":"2022061114022633400_B40","doi-asserted-by":"crossref","unstructured":"Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med\u20082002;347:790\u20136.","DOI":"10.1056\/NEJMoa021483"},{"key":"2022061114022633400_B41","doi-asserted-by":"crossref","unstructured":"Sato K, Qian J, Slezak JM, et al. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst\u20081999;91:1574\u201380.","DOI":"10.1093\/jnci\/91.18.1574"},{"key":"2022061114022633400_B42","doi-asserted-by":"crossref","unstructured":"Steiner T, Junker K, Burkhardt F, Braunsdorf A, Janitzky V, Schubert J. Gain in chromosome 8q correlates with early progression in hormonal treated prostate cancer. Eur Urol\u20082002;41:167\u201371.","DOI":"10.1016\/S0302-2838(01)00030-6"},{"key":"2022061114022633400_B43","doi-asserted-by":"crossref","unstructured":"Van Dekken H, Alers JC, Damen IA, et al. Genetic evaluation of localized prostate cancer in a cohort of forty patients: gain of distal 8q discriminates between progressors and nonprogressors. Lab Invest\u20082003;83:789\u201396.","DOI":"10.1097\/01.LAB.0000074889.76221.49"},{"key":"2022061114022633400_B44","doi-asserted-by":"crossref","unstructured":"Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol\u20082004;16:292\u2013306.","DOI":"10.1038\/modpathol.3800054"},{"key":"2022061114022633400_B45","doi-asserted-by":"crossref","unstructured":"DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet\u20082003;361:955\u201364.","DOI":"10.1016\/S0140-6736(03)12779-1"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/12\/13\/3961\/1963238\/3961.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/12\/13\/3961\/1963238\/3961.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T23:57:22Z","timestamp":1654991842000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/12\/13\/3961\/284707\/8q-Gain-Is-an-Independent-Predictor-of-Poor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,1]]},"references-count":45,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2006,7,3]]},"published-print":{"date-parts":[[2006,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-05-1977","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,1]]}}}